争议事件
以下收录公开来源中与该品牌相关的争议事件。列出一条并不表示过错已经证实。
返回词条共 1 条
2023
AbbVie就Brukinsa对BeiGene提起专利诉讼
提起诉讼
AbbVie旗下Pharmacyclics部门在特拉华州联邦法院起诉BeiGene,指称BeiGene的Brukinsa侵犯了AbbVie的Imbruvica专利。AbbVie寻求侵权宣告及赔偿;BeiGene表示将积极应对这些指控。
当事方说明的目的. AbbVie寻求侵权宣告及赔偿。
品牌回应
否认 — BeiGene
BeiGene said in a statement that it will “vigorously defend” against all allegations of patent infringement.
来源摘录
Through its complaint, filed the same day in federal court in Delaware, US, AbbVie is seeking a declaratory judgment of infringement, as well as damages.
AbbVie’s Pharmacyclics unit has filed a lawsuit against BeiGene, alleging that the biotech’s Brukinsa (zanubrutinib) infringes a patent on its own blood cancer drug Imbruvica (ibrutinib).
BeiGene said in a statement that it will “vigorously defend” against all allegations of patent infringement.